Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Tamil Nadu 603103, India.
Department of Nutrition, Institute of Medical Sciences, Faculty of Medicine, University of Oslo, Norway.
Int J Biochem Cell Biol. 2024 Aug;173:106616. doi: 10.1016/j.biocel.2024.106616. Epub 2024 Jul 9.
Extracellular vesicles (EVs) are important mediators of intercellular communication within the cardiovascular system, playing essential roles in physiological homeostasis and contributing to the pathogenesis of various cardiovascular diseases (CVDs). However, their potential as diagnostic biomarkers and therapeutic agents in rare cardiovascular diseases, such as valvular heart disease (VHD) and cardiomyopathies, remains largely unexplored. This review comprehensively emphasizes recent advancements in extracellular vesicle research, explicitly highlighting their growing significance in diagnosing and potentially treating rare cardiovascular diseases, with a particular focus on valvular heart disease and cardiomyopathies. We highlight the potential of extracellular vesicle-based liquid biopsies as non-invasive tools for early disease detection and risk stratification, showcasing specific extracellular vesicle-associated biomarkers (proteins, microRNAs, lipids) with diagnostic and prognostic value. Furthermore, we discussed the therapeutic promise of extracellular vesicles derived from various sources, including stem cells and engineered extracellular vesicles, for cardiac repair and regeneration through their ability to modulate inflammation, promote angiogenesis, and reduce fibrosis. By integrating the findings and addressing critical knowledge gaps, this review aims to stimulate further research and innovation in extracellular vesicle-based diagnostics and therapeutics of cardiovascular disease.
细胞外囊泡(EVs)是心血管系统细胞间通讯的重要介质,在生理稳态中发挥着重要作用,并有助于各种心血管疾病(CVDs)的发病机制。然而,它们作为诊断生物标志物和治疗剂在罕见心血管疾病(如瓣膜性心脏病(VHD)和心肌病)中的潜力在很大程度上尚未得到探索。本综述全面强调了细胞外囊泡研究的最新进展,特别强调了它们在诊断和潜在治疗罕见心血管疾病方面的重要性,特别关注瓣膜性心脏病和心肌病。我们强调了基于细胞外囊泡的液体活检作为早期疾病检测和风险分层的非侵入性工具的潜力,展示了具有诊断和预后价值的特定细胞外囊泡相关生物标志物(蛋白质、microRNAs、脂质)。此外,我们讨论了各种来源的细胞外囊泡(包括干细胞和工程化细胞外囊泡)通过调节炎症、促进血管生成和减少纤维化来治疗心脏损伤和再生的治疗潜力。通过整合研究结果并解决关键知识空白,本综述旨在促进基于细胞外囊泡的心血管疾病诊断和治疗的进一步研究和创新。